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ABSTRACT 21 
Objective: Bowel obstruction (MBO) is usually a pre-terminal event in patients with 22 
ovarian cancer. However, because of the lack of data in literature, decisions around 23 
surgical intervention, non resectional procedures or medical treatment of MBO in 24 
patients with ovarian cancer can not be lightly undertaken. We analyzed medical and 25 
surgical procedures, performance status, nutritional status, cachexia and their 26 
prognostic value in this group of patients. 27 
Methods: We retrospectively selected all consecutive patients with recurrent ovarian 28 
cancer who received medical or surgical treatment for MBO between October 2008 29 
and January 2014 at the Academic Department of Gynecological Oncology of 30 
Mauriziano Hospital of Turin (Italy).  31 
Results: We found 40 patients: 18 of them underwent medical treatment and 22 of 32 
them were submitted to surgery. In the group of surgery, the hospitalization was 33 
shorter (p: 0.02), the pain reduction was more effective (p: 0.001), the number of 34 
chemotherapy lines was higher (p: 0.03) and re-obstruction was more rare (p: 0.02). 35 
Between the two groups, we did not find any differences in post-palliation episodes 36 
of vomit (p: 0.83), type of diet (p: 0.34), ability to return home (p: 0.72) and death 37 
setting (p: 0.28). Median survival after palliation was longer in the group of surgery 38 
(p: 0.025). Cachexia, low performance status and poor nutritional status were 39 
significant predictors of worse survival after MBO, independently by the treatment. 40 
Conclusions: Surgery has to be considered in patients without serious 41 
contraindications, otherwise a medical protocol, including antisecretory drugs, is the 42 
standard of care in frail patients. 43 
 44 
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INTRODUCTION 45 
Bowel obstruction is defined as the situation in which the normal intestinal transit is 46 
abnormally delayed or completely stopped. It is a common complication in patients 47 
with end-stage cancer and it is estimated that malignant bowel obstruction (MBO) 48 
involves 3% of the patients admitted in Hospice. The reported frequency varies from 49 
25% to 50% in patients with advanced ovarian cancer [1]. Survival is generally poor, 50 
with a reported median survival of 1-3 months, but some studies have demonstrated 51 
survival of up to 1 year. 52 
In the patients with advanced ovarian cancer, more often the intestinal occlusion is 53 
due to the diffuse peritoneal carcinomatosis. MBO may be sometimes the 54 
consequence of the cancer treatment: adhesions from previous surgery, radiation 55 
enteritis, chronic ischemia, neurotoxicity from Vinca Alkaloids or narcotic intestinal 56 
syndrome from the use of opioids.  57 
Bowel obstruction can be partial or complete and can occur at single or multiple 58 
sites. Small bowel obstruction is more common than large bowel obstruction (61 vs 59 
33%) and both sites are involved in > 20% of patients [2].  60 
Therapy directed at MBO must achieve certain goals, such as allowing the patient to 61 
return home, restoration of oral intake and relief of abdominal distension and pain. 62 
Once the obstruction is relieved, a small proportion of patients is suitable for further 63 
treatment with chemotherapy. 64 
Although bowel obstruction in advanced ovarian cancer presents quite commonly, its 65 
management still remains a challenge, mainly because it has been the focus of very 66 
few clinical trials. Because of the lack of the evidences in literature, decisions around 67 
surgical intervention, non resectional procedures or medical treatment of malignant 68 
intestinal obstruction cannot be lightly undertaken. The survival benefit from the 69 
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different strategies is difficult to validate because of the heterogeneity of the 70 
populations studied in various trials, particularly with respect to the primary cancer 71 
type. Studies so far have measured perioperative mortality and morbidity but have 72 
not taken the quality of life (QOL) into account when measuring the success of any 73 
procedures [3]. 74 
The aim of the study was to compare the two different strategies, medical and 75 
surgical, in the management of MBO in ovarian cancer patients. We evaluated if 76 
operative and conservative approaches produce an effective and durable palliation in 77 
terms of QOL and survival. Furthermore, we investigated the prevalence of low 78 
performance status, poor nutritional status and cachexia in ovarian cancer patients 79 
with MBO and whether the results correlated with overall survival. 80 
 81 
MATERIAL AND METHODS 82 
All consecutive patients with recurrent ovarian cancer who experienced bowel 83 
obstruction between October 2008 and January 2014 at the Academic Department of 84 
Gynecological Oncology of Mauriziano Hospital of Turin (Italy) were identified 85 
through the discharging program of the Division. We excluded patients with MBO 86 
for other gynecological malignancies, non-epithelial or borderline ovarian cancer, 87 
patients with bowel obstruction for benign causes, patients with a history of previous 88 
or concurrent malignancy and patients with concomitant recto-vaginal fistula. 89 
The diagnosis of MBO was based on history, signs and symptoms, physical 90 
examination and radiological findings. At the moment of hospital admission, all 91 
patients underwent some laboratory tests and a chest-abdominal computed 92 
tomography (CT) to identify the site of bowel occlusion and to restage the disease. 93 
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Because the location of the MBO can determine the treatment options, we 94 
distinguished the site of obstruction in large, small and both small and large bowel.  95 
The selected patients received medical or surgical treatment. 96 
Medical management of the patients with MBO considered the following protocol: 97 
- Morphine Sulphate 60 mg, Haloperidol 1.5 mg, Octreotide 0.3 mg [4] 98 
through continuous subcutaneous pump infusion per day; 99 
- Dexamethasone 8 mg intravenous per day; 100 
- Stop oral intake; 101 
- Parenteral liquids. 102 
Surgical management consisted of the less invasive and most conservative 103 
interventions to palliate symptoms and to restore intestinal function.  104 
The significance of the palliative treatment was largely explained to the patients and 105 
for the surgical procedures an informed consensus was signed by the patient and by 106 
the surgeon. Patients and their families during the palliative care for the MBO were 107 
followed by the team of gynecological oncology, a nutritionist, a palliative care 108 
physician, a group of three colorectal surgeons and a nurse expert in ostomy 109 
management. All patients were visited by all the specialists during the process of 110 
care. At discharge, patients underwent chemotherapy, if indicated, or palliative care 111 
at home or in hospice.  112 
We collected the following data on the history of the patients relative to three stages: 113 
I- Before MBO: stage of the ovarian cancer at diagnosis (FIGO), date of the end 114 
of the primary treatment, date of the recurrence, platinum sensitivity, number of 115 
chemotherapy lines, secondary surgery and radiotherapy; 116 
II- Time of MBO: performance status (Karnofsky scale), nutritional status (PG-117 
SGA) [5-6], cachexia (CCSG) [7], body mass index (BMI - kg/m2), comorbidities, 118 
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date of MBO, vomit, pain (NRS), palpable abdominal mass, CT scan findings 119 
(peritoneal carcinomatosis, abdominal or extra-abdominal disease, ascites > 2 L and 120 
the site of obstruction), serum sodium (mEq/L) serum kalium (mEq/l), calcium 121 
(mg/dl), serum creatinin (mg/dl), total serum protein (g/dl), serum albumin (mg/dl), 122 
haemoglobin (g/dl), C-reactive protein (mg/l), medical or surgical management, type 123 
of surgical procedure, surgical morbidity and mortality, duration of the 124 
hospitalization (days); 125 
III-  After MBO: pain (NRS), vomit, type of diet at discharge (oral, oral and 126 
parenteral or parenteral), ability to return home, accesses to emergency department 127 
and re-hospitalization for re-obstruction and successive medical or surgical 128 
intervention, number of chemotherapy lines, death setting (hospital, hospice or 129 
home) and survival. 130 
The range from the end of the primary treatment and the diagnosis of relapsed cancer 131 
was defined disease free interval (DFI) and the recurrent disease was considered 132 
platinum sensitive when it reappeared after a DFI > 6 months.  133 
The study was approved by the Local Ethics Committee.  134 
 135 
Statistical analysis 136 
Differences in the groups were analyzed using the Student’s t-test for continuous 137 
variables or the U Mann-Whitney Test when a normal distribution was not assumed 138 
(Non parametric test); the Pearson chi-square test was adopted to compare 139 
frequencies. Overall survival curves were plotted according to the Kaplan–Meier 140 
product limit method and analyzed by the Log-Rank test. Multivariate analysis was 141 
performed using the Cox’s proportional hazards logistic regression. Alfa level of less 142 
than or equal to 0.05 were considered statistically significant.  143 
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RESULTS 144 
Patients characteristics 145 
Between October 2008 and January 2014, 53 patients were hospitalized in our 146 
division with the admission diagnosis of intestinal occlusion. Thirteen patients with 147 
MBO for endometrial, non-epithelial or borderline ovarian cancer, 5 patients with 148 
bowel obstruction for benign causes, 2 patients with a history of previous or 149 
concurrent malignancy and 3 patients with concomitant recto-vaginal fistula were 150 
excluded. Data from the remaining 40 patients with concomitant recurrent epithelial 151 
ovarian cancer and malignant bowel obstruction were collected. At ovarian cancer 152 
diagnosis, 4 patients were stage I-II and 36 patients were stage III-IV, according to 153 
FIGO. All patients underwent debulking surgery and all patients, except one, 154 
received neoadjuvant or first-line platinum based chemotherapy. Median DFI was 10 155 
months (range 3 - 96 months). In three cases, the diagnosis of recurrent disease was 156 
concomitant to MBO. Before MBO, the median number of chemotherapy line was 3 157 
lines (range 1 - 7). One patient was submitted to radiotherapy for a muscle-skeletal 158 
recurrence of the ileo-psoas region and one patient received radical secondary 159 
cytoreductive surgery. The median interval from the diagnosis of ovarian cancer to 160 
MBO was 26 months (range 3–149 months). The median age at first episode of MBO 161 
was 63 years (range 24 – 79 years). Nineteen patients suffered from at least one 162 
comorbidity and the most frequent was hypertension. Eighteen patients underwent 163 
medical treatment and 22 patients were submitted to surgery. Data of the patients at 164 
the moment of hospital admission for MBO are summarized in Table 1. We found 4 165 
clinical factors, amongst the 12 analyzed, who resulted significantly different 166 
between the two groups: performance and nutritional status, pain (NRS ≥ 7) and 167 
ascites. Considering the laboratory tests, only the levels of serum albumin were 168 
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significantly higher in the group undergoing surgery (p: 0.01). At hospital admission, 169 
after the radiological restaging (chest-abdomen CT), thirty-two patients were 170 
classified stage FIGO III C (macroscopic peritoneal metastasis beyond the pelvis 171 
more than 2 cm), three patients were classified FIGO IV A (pleural effusion) and five 172 
patients were classified FIGO IV B (three patients with liver metastasis, one with 173 
pulmonary hilum lymph nodes metastasis and one with muscle-skeletal metastasis). 174 
On the basis of the FIGO staging, no difference has been found between the two 175 
groups. 176 
Medical treatment 177 
The medical protocol controlled symptoms within 4 days (range 1 – 9 days) and the 178 
median hospitalization duration was 8 days (range 3-25 days). No side effects were 179 
reported. Data about diet, re-obstruction, vomit and chemotherapy after MBO are 180 
reported in Table 2. Median survival after MBO for the group of medical treatment 181 
was 5.7 months (range: < 1 - 8.4 months). At the moment, 17 patients died, 4 182 
(22.2%) in hospital, 3 (16.7%) in hospice, 10 (55.5%) at home and 1 patient is still 183 
alive with disease.  184 
 185 
Surgical treatment 186 
Surgical procedures included 4 (18.9%) bowel resection and anastomosis, 9 (40.9%) 187 
bowel resection and ostomy (2 colostomy and 7 ileostomy), 8 (36.4%) exclusive 188 
ostomy (1 colostomy and 7 ileostomy) and 1 (4.5%) positioning of colonic stent. One 189 
patient (4.5%), who underwent large bowel resection and anastomosis, had a 190 
postoperative recto-vaginal fistula and required a re-intervention and ileostomy. The 191 
mortality within 30 days from surgery was 4.5% (1 case), who died from progression 192 
of tumour. Five patients (22.7%) underwent surgery within 24 hours from the 193 
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hospital admission, but there were no more complications or longer hospitalization in 194 
this group. Median hospitalization was 14 days (range 8 - 30 days). Data about diet, 195 
re-obstruction, vomit and chemotherapy after MBO are reported in Table 2. The 196 
median survival after MBO for the group of surgical treatment was 13.6 months 197 
(10.1 – 17.0 months). Nineteen patients died of disease, 6 (27.3%) in hospital, 4 198 
(18.9%) in hospice, 9 (40.9%) at home, and 3 (13.6%) patients are still alive with 199 
disease. 200 
 201 
Comparison of treatments 202 
Median hospitalization was shorter for the medical than for the surgical treatment (p: 203 
0.02). Pain reduction one week after palliation was significantly more effective in the 204 
surgical group (p: 0.001). The number of accesses to emergency department and re-205 
hospitalization for re-obstruction was significantly higher in the group of medical 206 
treatment and in these patients the medical protocol was applied or reapplied (p: 207 
0.02) (Table 2). After intestinal occlusion, the number of chemotherapy lines was 208 
higher in the surgical group (p: 0.03). Between the two groups we did not find any 209 
difference in post-palliation episodes of vomit (p: 0.83), type of diet (p: 0.34), ability 210 
to return home (p: 0.72) and death setting (p: 0.28). The median survival after 211 
palliation was longer in the group of surgery (p: 0.025) (Fig. 1).  212 
In the group of surgery, patients had a better performance and nutritional status, but 213 
no differences were shown about cachexia (Table 1). Cachexia, defined by the CCSG 214 
criteria, increased the risk of death with an odds ratio of 3.2 (95% C.I. 1.5-6.6) (p: 215 
0.001), the performance status amplified the risk of death with an odds ratio of 2.3 216 
(95% C.I. 1.4-3.7) (p: 0.0001) and having a poor nutritional status (SGA-C) enlarged 217 
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the risk of death with an odds ratio of 4.7 (95% C.I. 1.4-14.9) (p: 0.008), compared to 218 
well nourished patients (SGA-A).  219 
In the multivariate logistic regression analysis (Cox proportional hazard model), 220 
including as co-variates all the considered variables, CCSG cachexia and 221 
performance status resulted independent prognostic factors (p: 0.0001) (Table 3).  222 
 223 
DISCUSSION 224 
 225 
Bowel obstruction is usually a pre-terminal event in patients with ovarian cancer. For 226 
this reason, the relief of symptoms is the first aim of the treatment of these patients, 227 
but the clinical management is not completely defined. Many treatment options, 228 
medical approaches, endoscopic procedures and surgical interventions have been 229 
proposed, but current evidences do not provide a standard of care. Modern medical 230 
protocols include the use of somatostatine analogs (Octreotide), that inhibits the 231 
release of gastro-intestinal secretions and regularizes the intestinal motility [4]. 232 
Surgery remains a discussed issue in patients with advanced cancer.  233 
In patients with MBO, the major perplexities concern the success of conservative 234 
treatment and the safety of operative management. Tang et al. reported that only 235 
3.8% of complete obstruction resolved with conservative management [8]. In a later 236 
study, 43% of 329 patients were successfully treated conservatively but with a re-237 
obstruction rate of 40.5% [9]. On the other hand, palliative surgery was associated 238 
with a reported morbidity of 5% – 49% and mortality of 5% – 15% [10-11-12]. 239 
Major operative complications are fistulas, anastomotic leaks and sepsis. In our 240 
study, the post-operative morbidity and mortality were low (4.5% each). We 241 
registered only 1 case of recto-vaginal fistula, who required a re-intervention and 242 
ileostomy, and 1 case of death within 30 days from surgery due to tumour 243 
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progression. In similar recent studies, Kolomainen et al. found an operative mortality 244 
and morbidity rate of 18% and 27%, respectively [13], and Perri et al. described a 245 
mortality rate of 14.7% within 30 days[14]. Medina-Franco et al. described a hospital 246 
mortality rate of 10.8% and a postoperative morbidity of 16.2%, and the factors 247 
associated with a significant increase of surgical mortality were: advanced patient 248 
age, hypoalbuminemia, ovarian neoplasms and poor performance status [14].  249 
In patients with MBO and recurrent ovarian cancer, the reported median survival is 250 
3–6 months after palliation [15-16]. More recent series reported a median survival of 251 
11.4 – 12.6 months in patients undergoing surgery for MBO versus 3.7 – 3.9 months 252 
for non-surgical patients [17]. In our study, the median survival after palliation was 253 
13.6 months for the group of surgery and 5.7 months for the group of medical 254 
treatment. Mangili et al. also found a longer survival in the surgical group [18] and 255 
Kolomainen et al. reported a median overall survival after surgical management of 256 
MBO around 3 months (range: 2 days – 6 years) [13]. Table 4 compares the reported 257 
survival after palliation in the literature.  258 
In the present study, amongst the analyzed factors, the two groups of treatment 259 
showed 5 significant differences: performance status, nutritional status, pain, ascites 260 
and albumin. There were not any differences between the two groups in terms of age, 261 
FIGO stadiation, number of previous chemotherapy lines, DFI, time from ovarian 262 
cancer diagnosis and MBO and time from the last chemotherapy infusion. In the 263 
group of surgery, the number of chemotherapy lines after MBO was higher, 15 264 
patients (68.2%) received at least one line and 5 patients (22.7%) completed more 265 
than one line (p: 0.03). 266 
In our series, many QOL criteria were considered in the analysis. Pain reduction was 267 
more effective in the surgical group and re-obstruction was more frequent in the 268 
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group of medical treatment. Between the two groups we did not find any difference 269 
in post-palliation episodes of vomit, type of diet and ability to return home. As 270 
reported, 2 essential QOL factors, pain reduction and re-obstruction, were 271 
significantly improved by surgical palliation. In case of re-obstruction, all patients 272 
received medical treatment. Two reports, each describing a small series of ovarian 273 
cancer patients who underwent exploratory laparotomy for recurrent bowel 274 
obstruction, reported successful palliation in 30% of cases [2-3]. In accordance with 275 
the cited studies, because of the high morbidity rate, the rapid development of 276 
subsequent bowel obstructions and the limited survival, we agree that a non-surgical 277 
approach is probably preferable for patients who experience repeated bowel 278 
obstruction. Because of the retrospective design, we lack data from some overall 279 
QOL questionnaires [18-19].  280 
Considering some selection bias, our data suggest that patients who underwent 281 
palliative surgery achieve more effective survival and QOL improvements, but 282 
because of the reported implications, the decision to proceed with surgical palliation 283 
in patients with ovarian cancer and MBO has to be carefully evaluated for each 284 
individual patient. 285 
Several studies have focused their attention to the identification of some prognostic 286 
factors for the selection of patients who may benefit from surgery. Mangili et al. 287 
suggested that the surgical approach seems to be useful for patients with life 288 
expectancy greater than 2 months [20]. Studies identified age, ascites, previous 289 
radiotherapy, multiple bowel obstructions, carcinomatosis, palpable masses and short 290 
interval from diagnosis to obstruction as clinical indicators of poor prognosis after 291 
surgery [13-21-22-23-24]. Henry et al. proposed a nomogram of 4 identified risk 292 
factors: carcinomatosis on imaging, leukocytosis, normal albumin and non 293 
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gynecologic cancer, that revealed which patients with complete small bowel 294 
obstruction might benefit from surgery [25]. However, because only the 17% of the 295 
included patients had gynecologic malignancies, their findings might not be fully 296 
applicable to gynecological oncology. Finally, in the study of Perri et al., a 4-variable 297 
score was correlated with the 30 days and 60 days overall survival after surgical 298 
palliation for MBO in gynecologic malignancies: 2.7% and 5.4%, respectively (score 299 
0-1), and 40% and 73.3%, respectively (score 3-5). The score includes age above 60, 300 
ascites of more than 2 L, non-ovarian primary tumor and albumin < 2.5 g/dl [3]. The 301 
first three factors were assigned a value of 1 if present and 0 if not. Albumin < 2.5 302 
mg/dl was assigned a value of 2 if present and 0 if not. The proposed scoring system 303 
is easy to apply and might facilitate decision of the healthcare team and information 304 
of patients and families. The major limitation of this score is that it does not take into 305 
account information about performance status. 306 
Different tools have been proposed for cancer malnutrition and wasting assessment. 307 
They have been largely confirmed in gastro-intestinal cancer patients, but they have 308 
never been validated in ovarian cancer neoplasm. We designed the second part of the 309 
study to identify the role of performance status, nutritional status and cachexia in 310 
ovarian cancer patients with MBO and their association with survival after palliation, 311 
independently by the treatment. Thirteen patients (32.5%) had a low performance 312 
status and, finally, in accordance with PG-SGA classification, 8 patients (20%) were 313 
“severely malnourished”. Figures 2-3-4 show that low performance status, CCSG 314 
cachexia and poor nutritional status were all significant predictors of worse survival 315 
after MBO. To the best of our knowledge, the present study is the first that applied 316 
these assessment tools in such homogeneous group of patients with advanced ovarian 317 
carcinoma. The CCSG definition of cachexia was first introduced in a study of 318 
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patients with pancreatic carcinoma in which cachexia was found to be related to the 319 
patients’ survival [26]. In that study, 60% of the patients had cachexia and the HR for 320 
overall survival was 2.23, close to our findings. These observations suggest that the 321 
CCSG definition of cachexia should be applicable also in advanced ovarian 322 
carcinoma.  In this study, CCSG cachexia and low performance reached statistical 323 
significance in both unadjusted and adjusted survival analyses and were the most 324 
powerful predictors of survival. The sample size of the study was limited, and further 325 
investigations are required to confirm the prognostic value of the nutrition and 326 
cachexia assessments.  327 
In our report, especially for the group of surgery, the long prognosis, the low rates of 328 
postoperative morbidity and mortality and the high number of patients who received 329 
chemotherapy after MBO probably reflect the good performance status of the 330 
patients. Furthermore, previous reports date back several decades and so they do not 331 
take into account the substantial improvements of the current medical protocols, 332 
surgical techniques and anaesthesia. On the basis of our experience, we support the 333 
hypothesis that performance and nutritional status and cachexia may address the 334 
choice of the treatment. 335 
All series, including ours, are retrospective and include a small numbers of patients, 336 
but our study solely comprised ovarian cancer patients treated in a relatively short 337 
period. In the analysis, we focused specific attention to QOL outcomes. Moreover, 338 
our results come from a single institution and patients were assessed by a 339 
multidisciplinary team.  340 
In the setting of palliative care, a randomized trial is challenging [27]. A trial 341 
comparing therapies for MBO will help to define therapy and identify selection 342 
criteria. Untill now, no comparative trials have been performed on the role of the 343 
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therapeutic strategies for MBO. To prove the effects of any given treatment, 344 
hundreds of patients would need to be recruited. A trial in this scenery is hampered 345 
by many individual differences between patients and by the myriad of advanced 346 
medical and surgical protocols. Currently, in the absence of a shared protocol, it is 347 
our intention to validate our findings in a prospective study. 348 
In conclusion, malignant bowel obstruction represents a common end-of-life event in 349 
ovarian cancer patients. Because of its complexity and frailty of involved patients, a 350 
multidisciplinary and collaborative approach is mandatory for an optimal clinical 351 
management and palliation of MBO. In a palliative setting, the most important goal 352 
is to identify the patient's expectations, because they are largely subjective for each 353 
individual patient [28]. For these reasons, patients, and eventually their families, 354 
must be informed about their health and life expectancy. Surgery has to be 355 
considered in patients without serious contraindications, otherwise a combination of 356 
opioids, anti-emetics, corticosteroids and antisecretory drugs is the mainstay in 357 
patients with poor general conditions. 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
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